0001415889-23-004513.txt : 20230308 0001415889-23-004513.hdr.sgml : 20230308 20230308180021 ACCESSION NUMBER: 0001415889-23-004513 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230306 FILED AS OF DATE: 20230308 DATE AS OF CHANGE: 20230308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dake Benjamin T CENTRAL INDEX KEY: 0001869248 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40544 FILM NUMBER: 23717477 MAIL ADDRESS: STREET 1: C/O AEROVATE THERAPEUTICS, INC. STREET 2: 200 BERKELEY STREET, FLOOR 18 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc. CENTRAL INDEX KEY: 0001798749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 831377888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-443-2400 MAIL ADDRESS: STREET 1: 930 WINTER STREET STREET 2: SUITE M-500 CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4-03082023_060307.xml X0306 4 2023-03-06 0001798749 Aerovate Therapeutics, Inc. AVTE 0001869248 Dake Benjamin T C/O AEROVATE THERAPEUTICS, INC. 930 WINTER STREET, SUITE M-500 WALTHAM MA 02451 false true false false SEE REMARKS Common Stock 2023-03-06 4 M 0 2412 1.74 A 2412 D Common Stock 2023-03-06 4 M 0 7870 2.14 A 10282 D Common Stock 2023-03-06 4 S 0 10067 23.7098 D 215 D Common Stock 2023-03-06 4 S 0 215 24.4977 D 0 D Stock Option (Right to Buy) 1.74 2023-03-06 4 M 0 906 0 D 2030-09-03 Common Stock 906 9055 D Stock Option (Right to Buy) 1.74 2023-03-06 4 M 0 1506 0 D 2030-09-03 Common Stock 1506 25616 D Stock Option (Right to Buy) 2.14 2023-03-06 4 M 0 1018 0 D 2031-04-01 Common Stock 1018 25460 D Stock Option (Right to Buy) 2.14 2023-03-06 4 M 0 6852 0 D 2031-04-01 Common Stock 6852 185019 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.28 to $24.002, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.30 to $24.96, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Officer Title: President, Chief Operating Officer and Secretary /s/ George A. Eldridge, Attorney-in-Fact 2023-03-08